Wockhardt WOCKPHARMA
Antibiotic discovery company - first Indian-discovered NCE antibiotic approved by the US FDA (Zaynich, 2026) - plus generics in India, UK and emerging markets
Mapped in 1 theme: Pharmaceuticals.
Where Wockhardt sits in the supply chain
Wockhardt appears in 1 supply-chain layer in one theme, Pharmaceuticals.
Pharmaceuticals › Specialty & innovation (R&D)
OwnerOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 2,798 | 3,012 | 3,373 |
| Net profit | −472 | −57 | 199 |
Latest-year revenue ₹3,373 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Zaynich (cefepime-zidebactam) approved by USFDA (mid-2026) for drug-resistant infections; EMA filing accepted for accelerated assessment
- Novel antibiotic pipeline (Miqnaf/nafithromycin approved in India)
- FY26 was the first profitable year after a long loss run
Risks
- Commercial success of a new antibiotic in the US is notoriously hard (hospital uptake, stewardship)
- History of USFDA import alerts and leverage
- Valuation now prices in a successful Zaynich launch
Common questions
What does Wockhardt do?
Antibiotic discovery company - first Indian-discovered NCE antibiotic approved by the US FDA (Zaynich, 2026) - plus generics in India, UK and emerging markets.
Where does Wockhardt sit in the supply chain?
Wockhardt (NSE: WOCKPHARMA) is mapped in 1 supply-chain layer: Specialty & innovation (R&D) (Pharmaceuticals).
Who are Wockhardt's peers?
In the Specialty & innovation (R&D) layer of Pharmaceuticals: Sun Pharmaceutical Industries, Glenmark Pharmaceuticals, Zydus Lifesciences, Lupin and SPARC (Sun Pharma Advanced Research Company).
What is Wockhardt's market cap and valuation?
As of 30 Oct 2026: market cap ₹30,918 Cr, P/E 77.6x, ROCE 7.5%, ROE 6.1%, dividend yield 0%.